Cyclo Therapeutics Initiated at Buy by HC Wainwright & Co.
Cyclo Therapeutics Initiated at Buy by HC Wainwright & Co.
Dow JonesMay 1 06:23 ET
Analysts Are Bullish on These Healthcare Stocks: Exelixis (EXEL), Cyclo Therapeutics (CYTH)
TipRanksMay 1 06:17 ET
Express News | Cyclo Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $3
ReutersMay 1 06:06 ET
Cyclo Therapeutics Initiated at Buy by Ascendiant Capital
Cyclo Therapeutics Initiated at Buy by Ascendiant Capital
Dow JonesApr 22 05:47 ET
Express News | Ascendiant Capital Initiates Coverage On Cyclo Therapeutics With Buy Rating, Announces Price Target of $2.6
Moomoo 24/7Apr 22 05:40 ET
Cyclo Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 124.14% Ascendiant Capital → $2.6 Initiates Coverage On → Buy 09/27/2023 244.83% Maxim Group →
BenzingaApr 22 05:35 ET
Analysts Offer Insights on Healthcare Companies: Cyclo Therapeutics (CYTH), CytomX Therapeutics (CTMX) and Pacific Biosciences (PACB)
TipRanksApr 22 04:20 ET
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. Biora Therapeutics (NASDAQ:BIOR) share
BenzingaApr 18 16:31 ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersOneMedNet (NASDAQ:ONMD) shares moved upwards by 75.9% to $1.39 during Tuesday's after-market session. The market value of their outstanding shares is at $44.8 million. Aesthetic Medical Intl (N
BenzingaApr 2 16:31 ET
Express News | Cyclo Therapeutics Receives Decision To Grant European Patent Titled 'METHODS FOR TREATING ALZHEIMER'S DISEASE WITH HP-[BETA]-CYCLODEXTRIN'
Moomoo 24/7Apr 2 14:31 ET
Buy Rating Affirmed for Cyclo Therapeutics on Strong Clinical and Financial Prospects
TipRanksMar 19 15:35 ET
Express News | Cyclo Therapeutics FY23 EPS $(1.23) Up From $(1.83) YoY; Revenue $1.076M Down From $1.375M YoY
Moomoo 24/7Mar 18 09:11 ET
Press Release: Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update Continued progress of pivotal Phase 3 study (TransportNPC(TM)) evaluating Trappsol(R) Cyclo(TM) for the treatm
Dow JonesMar 18 09:05 ET
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through scie
Cyclo TherapeuticsMar 18 00:00 ET
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol Cyclo for the Treatment of Alzheimer's Disease
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medici
BusinesswireMar 14 09:34 ET
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
Stockhouse Mar 13 17:04 ET
Express News | Cyclo Therapeutics Announces Allowance Of Patent Application For Treatment Of Alzheimer's Disease From USPTO
Moomoo 24/7Jan 29 09:15 ET
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease From the U.S. Patent and Trademark Office
Business WireJan 29 09:15 ET
Cyclo Therapeutics Regains Compliance With Nasdaq Standards
TipRanksJan 23 03:00 ET
12 Health Care Stocks Moving In Monday's Intraday Session
GainersAtreca (NASDAQ:BCEL) stock rose 52.7% to $0.36 during Monday's regular session. The market value of their outstanding shares is at $14.1 million. Cyclo Therapeutics (NASDAQ:CYTH) shares rose 29
BenzingaJan 15 12:30 ET
No Data
No Data